Despite the robust clinical activity exerted by osimertinib, a majority of patients eventually exhibit disease progression while receiving this drug.  Resistance to osimertinib includes both on-target and off-target mechanisms.  With the use of osimertinib for advanced EGFR-mutant NSCLC increasing, the development of targeted therapies toward osimertinib resistance represents an unmet medical need.  To support research …Read More >

Successful application of nucleic acid therapeutics faces many challenges, including delivery efficiency and off-target effects.  To address these challenges, WuXi AppTec offers a full suite of nucleic acid-related services, including target validation, in vitro screening and cell-based functional assays, drug exposure analysis, biodistribution evaluation, PK/PD/efficacy testing, and safety assessment.  Leverage our comprehensive platform to accelerate …Read More >

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models.  WuXi AppTec offers validated, Enhertu-induced resistant tumor models to support project teams focused …Read More >

Screen your compounds across our comprehensive cell screening panel of over 600 authenticated, validated human cancer cell lines covering 50 cancer types.  We provide single agent and combination compound screening for potency and synergy, and bioinformatics analysis for mechanistic studies and biomarker discovery related to drug responses.  We also offer an extensive KRAS mutant cell …Read More >

Atopic dermatitis (AD) is the most common, chronic inflammatory skin disease.  To support drug discovery research in this area, WuXi AppTec offers a broad platform of validated, in vivo AD models.  Our panel includes DNCB, DNFB, and MC903-induced AD models.  Study readouts include histopathology scoring and measurements of serum IgE levels, transepidermal water loss, and …Read More >

Cell migration, invasion, and adhesion are pivotal steps in cancer metastasis.  To support research in this field, WuXi AppTec offers in vitro transwell migration and invasion assays using multiple cell types for assessing cell migratory behavior.  In addition, our in vivo metastasis panel includes a broad range of brain, bone, and liver xenograft models covering …Read More >

WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening.  Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc reporter cell lines, and validated assays (using co-cultures of Raji or A375 tumor cells) to evaluate the activity of CARs, TCRs, and bispecific antibodies.  Leverage our portfolio of reporter cell lines to accelerate your research! …Read More >

Our in vivo alopecia platform is comprised of both non-cicatricial and cicatricial alopecia models, including skin graft-induced alopecia areata (AA) in C3H/HeJ mice, cyclophosphamide-induced alopecia in C57BL/6 mice, and androgenetic alopecia (AGA) in C57BL/6 mice. Discover our comprehensive panel of in vivo pharmacology models by clicking here

Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell lysis and immune stimulation and can be optimized for enhanced tumor selectivity.  WuXi AppTec offers a comprehensive platform of OV-related services, including virus engineering and validation, immune profiling and lysis assays, tumor cell selectivity assays, …Read More >